Dr. Danielle Cabral, MD
Neurology (Neurology Physician)
801 W Maryland Ave
Phoenix, AZ 85013
Who else practices at this address →
Maricopa County includes primary care (13% of residents) and dental (0% of residents) and mental health (4% of residents) shortage areas. About shortage areas
Medicare and federal program status
Opted out of Medicare from October 1, 2025 through October 1, 2027. Medicare does not pay for this clinician’s services: patients with Medicare sign a private contract and pay the clinician directly. They can still order tests and refer Medicare patients to other providers.
Source: CMS Medicare Opt Out Affidavits (record last updated October 21, 2026). Opting out is a legal choice many clinicians make, often to run a cash or concierge practice.
At a glance
- In the NPI registry since
- 2011
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2011Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology Physician primary
AZ license 55944
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare patients and services
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 108 | 77 |
| Established patient office or other outpatient visit, 30-39 minutes | 52 | 45 |
| New patient office or other outpatient visit, 60-74 minutes | 22 | 22 |
| Psychiatric diagnostic evaluation | 14 | 14 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Donepezil Hcl Other prescribers in Phoenix, AZ | 49 |
| Memantine Hcl Other prescribers in Phoenix, AZ | 21 |
| Escitalopram Oxalate Other prescribers in Phoenix, AZ | 14 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 4 companies reported 53 payments worth $97,188 in total to this clinician.
| Eli Lilly and Company | $45,568 |
|---|---|
| Lilly USA, LLC | $44,351 |
| Eisai Inc. | $7,221 |
| C2n Diagnostics, LLC | $47.35 |
| Compensation for services other than consulting (speaking, faculty) | $45,788 |
|---|---|
| Consulting Fee | $33,820 |
| Travel and Lodging | $10,524 |
| Speaking at a medical education program | $6,860 |
| Food and Beverage | $197 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Eli Lilly and Company Oct 29, 2025 | Consulting Fee KISUNLA · Neuroscience | $11,138 |
| Lilly USA, LLC Mar 28, 2025 | Travel and Lodging travel to BEIJING, China · in-kind | $9,910 |
| Lilly USA, LLC Apr 3, 2025 | Consulting Fee KISUNLA · Neuroscience | $7,988 |
| Lilly USA, LLC Aug 28, 2025 | Compensation for services other than consulting (speaking, faculty) KISUNLA · Neuroscience | $5,250 |
| Eli Lilly and Company Sep 18, 2025 | Compensation for services other than consulting (speaking, faculty) KISUNLA · Neuroscience | $4,463 |
| Eli Lilly and Company Apr 18, 2025 | Compensation for services other than consulting (speaking, faculty) KISUNLA · Neuroscience | $4,200 |
| Eli Lilly and Company Apr 11, 2025 | Consulting Fee KISUNLA · Neuroscience | $4,200 |
| Eli Lilly and Company Sep 19, 2025 | Consulting FeeCompany’s descriptionSERVICES TO SUPPORT RESEARCH RELATED ACTIVITIES | $3,938 |
| Lilly USA, LLC Apr 3, 2025 | Consulting Fee KISUNLA · Neuroscience | $2,625 |
| Eli Lilly and Company Nov 26, 2025 | Compensation for services other than consulting (speaking, faculty) | $2,625 |
All 44 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Eli Lilly and Company Nov 26, 2025 | Compensation for services other than consulting (speaking, faculty) | $2,625 |
| Eli Lilly and Company Nov 26, 2025 | Compensation for services other than consulting (speaking, faculty) | $2,100 |
| Eli Lilly and Company Nov 26, 2025 | Compensation for services other than consulting (speaking, faculty) | $1,850 |
| Eli Lilly and Company Nov 26, 2025 | Compensation for services other than consulting (speaking, faculty) | $1,850 |
| Eli Lilly and Company Nov 26, 2025 | Compensation for services other than consulting (speaking, faculty) | $525 |
| Lilly USA, LLC Oct 30, 2025 | Compensation for services other than consulting (speaking, faculty) KISUNLA · Neuroscience | $1,050 |
| Eli Lilly and Company Oct 29, 2025 | Consulting Fee KISUNLA · Neuroscience | $11,138 |
| Eli Lilly and Company Oct 29, 2025 | Compensation for services other than consulting (speaking, faculty) KISUNLA · Neuroscience | $2,100 |
| Lilly USA, LLC Oct 29, 2025 | Compensation for services other than consulting (speaking, faculty) KISUNLA · Neuroscience | $2,100 |
| Lilly USA, LLC Oct 29, 2025 | Compensation for services other than consulting (speaking, faculty) KISUNLA · Neuroscience | $800 |
| Lilly USA, LLC Sep 26, 2025 | Compensation for services other than consulting (speaking, faculty) KISUNLA · Neuroscience | $2,100 |
| Lilly USA, LLC Sep 26, 2025 | Compensation for services other than consulting (speaking, faculty) KISUNLA · Neuroscience | $800 |
| Lilly USA, LLC Sep 23, 2025 | Compensation for services other than consulting (speaking, faculty) KISUNLA · Neuroscience | $2,100 |
| Lilly USA, LLC Sep 23, 2025 | Compensation for services other than consulting (speaking, faculty) KISUNLA · Neuroscience | $800 |
| Eli Lilly and Company Sep 19, 2025 | Consulting FeeCompany’s descriptionSERVICES TO SUPPORT RESEARCH RELATED ACTIVITIES | $3,938 |
| Eli Lilly and Company Sep 18, 2025 | Compensation for services other than consulting (speaking, faculty) KISUNLA · Neuroscience | $4,463 |
| Eli Lilly and Company Sep 18, 2025 | Compensation for services other than consulting (speaking, faculty) KISUNLA · Neuroscience | $1,850 |
| Eli Lilly and Company Sep 3, 2025 | Compensation for services other than consulting (speaking, faculty) KISUNLA · Neuroscience | $525 |
| Lilly USA, LLC Aug 28, 2025 | Compensation for services other than consulting (speaking, faculty) KISUNLA · Neuroscience | $5,250 |
| Lilly USA, LLC Aug 19, 2025 | Compensation for services other than consulting (speaking, faculty) KISUNLA · Neuroscience | $1,050 |
| Lilly USA, LLC Aug 4, 2025 | Compensation for services other than consulting (speaking, faculty) KISUNLA · Neuroscience | $2,100 |
| Lilly USA, LLC Aug 4, 2025 | Compensation for services other than consulting (speaking, faculty) KISUNLA · Neuroscience | $800 |
| Eisai Inc. May 22, 2025 | Speaking at a medical education program Leqembi · Neurology | $1,225 |
| Eisai Inc. May 22, 2025 | Speaking at a medical education program Leqembi · Neurology | $490 |
| Eisai Inc. May 9, 2025 | Consulting Fee Leqembi · Neurology | $245 |
| Eisai Inc. Apr 30, 2025 | Speaking at a medical education program Leqembi · Neurology | $1,225 |
| Eisai Inc. Apr 30, 2025 | Speaking at a medical education program Leqembi · Neurology | $490 |
| Eli Lilly and Company Apr 18, 2025 | Compensation for services other than consulting (speaking, faculty) KISUNLA · Neuroscience | $4,200 |
| Eli Lilly and Company Apr 18, 2025 | Compensation for services other than consulting (speaking, faculty) KISUNLA · Neuroscience | $1,850 |
| Eli Lilly and Company Apr 11, 2025 | Consulting Fee KISUNLA · Neuroscience | $4,200 |
| Eli Lilly and Company Apr 11, 2025 | Consulting Fee KISUNLA · Neuroscience | $1,850 |
| Eli Lilly and Company Apr 6, 2025 | Travel and Lodging travel to SAN DIEGO, AZ · in-kind | $284 |
| Eli Lilly and Company Apr 6, 2025 | Travel and Lodging travel to SAN DIEGO, AZ · in-kind | $222 |
| Lilly USA, LLC Apr 3, 2025 | Consulting Fee KISUNLA · Neuroscience | $7,988 |
| Lilly USA, LLC Apr 3, 2025 | Consulting Fee KISUNLA · Neuroscience | $2,625 |
| Eisai Inc. Apr 3, 2025 | Speaking at a medical education program Leqembi · Neurology | $1,225 |
| Eisai Inc. Apr 3, 2025 | Speaking at a medical education program Leqembi · Neurology | $490 |
| Lilly USA, LLC Mar 28, 2025 | Travel and Lodging travel to BEIJING, China · in-kind | $9,910 |
| Lilly USA, LLC Mar 28, 2025 | Travel and Lodging travel to BEIJING, China · in-kind | $108 |
| Eisai Inc. Mar 6, 2025 | Speaking at a medical education program Leqembi · Neurology | $1,225 |
| Eisai Inc. Mar 6, 2025 | Speaking at a medical education program Leqembi · Neurology | $490 |
| Lilly USA, LLC Feb 26, 2025 | Consulting Fee KISUNLA · Neuroscience | $1,838 |
| Lilly USA, LLC Jan 28, 2025 | Compensation for services other than consulting (speaking, faculty) KISUNLA · Neuroscience | $2,100 |
| Lilly USA, LLC Jan 28, 2025 | Compensation for services other than consulting (speaking, faculty) KISUNLA · Neuroscience | $800 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 2 companies. The companies reported $166,560 in research payments for these studies, mostly to the institutions running them.
- A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease
Eisai Inc. - A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)
E.r. Squibb & Sons, L.l.c. · Recruiting · NCT05511363 - Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
E.r. Squibb & Sons, L.l.c. · Recruiting · NCT05980949 - A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)
E.r. Squibb & Sons, L.l.c. · Recruiting · NCT06126224
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.